KR20210054598A - 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 - Google Patents

안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 Download PDF

Info

Publication number
KR20210054598A
KR20210054598A KR1020217013486A KR20217013486A KR20210054598A KR 20210054598 A KR20210054598 A KR 20210054598A KR 1020217013486 A KR1020217013486 A KR 1020217013486A KR 20217013486 A KR20217013486 A KR 20217013486A KR 20210054598 A KR20210054598 A KR 20210054598A
Authority
KR
South Korea
Prior art keywords
adamts13
formulation
approximately
stabilized
preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217013486A
Other languages
English (en)
Korean (ko)
Inventor
하 페터 마티센
페터 엘 투레섹
한스-페터 슈바르츠
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Priority to KR1020227034508A priority Critical patent/KR20220139456A/ko
Publication of KR20210054598A publication Critical patent/KR20210054598A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
KR1020217013486A 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 Ceased KR20210054598A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227034508A KR20220139456A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
US61/244,353 2009-09-21
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035791A Division KR20190137954A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034508A Division KR20220139456A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Publications (1)

Publication Number Publication Date
KR20210054598A true KR20210054598A (ko) 2021-05-13

Family

ID=43598388

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020187023806A Ceased KR20180095738A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020247043292A Ceased KR20250008986A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020217013486A Ceased KR20210054598A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020127009803A Active KR101891646B1 (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020197035791A Ceased KR20190137954A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020227034508A Ceased KR20220139456A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020187023806A Ceased KR20180095738A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020247043292A Ceased KR20250008986A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020127009803A Active KR101891646B1 (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020197035791A Ceased KR20190137954A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020227034508A Ceased KR20220139456A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Country Status (21)

Country Link
US (9) US8623352B2 (enExample)
EP (5) EP4467160A3 (enExample)
JP (2) JP5819303B2 (enExample)
KR (6) KR20180095738A (enExample)
CN (2) CN102573792B (enExample)
AU (1) AU2010295299B2 (enExample)
BR (1) BR112012006283B1 (enExample)
CA (1) CA2774556A1 (enExample)
DK (4) DK4218797T5 (enExample)
EA (1) EA024267B1 (enExample)
ES (4) ES2579906T3 (enExample)
FI (2) FI3834841T3 (enExample)
FR (1) FR24C1049I2 (enExample)
HR (1) HRP20160295T1 (enExample)
HU (1) HUE028688T2 (enExample)
IN (1) IN2012DN02645A (enExample)
MX (3) MX339205B (enExample)
NZ (1) NZ598839A (enExample)
PL (4) PL3167897T3 (enExample)
PT (2) PT4218797T (enExample)
WO (1) WO2011035335A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670103B1 (ko) 2008-12-05 2016-10-27 박스알타 인코퍼레이티드 폰빌레브란트 인자의 ａｄａｍｔｓ１３－매개 생체내 절단을 측정하는 방법 및 그의 사용
BR112012006283B1 (pt) 2009-09-21 2022-03-15 Takeda Pharmaceutical Company Limited Formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e, usos de adamts13
AU2013221317B2 (en) * 2012-02-16 2017-07-06 Pangu Biopharma Limited Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
US10441531B2 (en) 2012-11-09 2019-10-15 Bloodworks Protein stabilizing factors
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
EP4285930A3 (en) * 2014-06-26 2024-02-28 Amgen Inc. Protein formulations
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
EP3401685B1 (en) * 2016-01-08 2021-12-01 Kyoto University Diagnostic method and medicine comprising adamts13 as main ingredient
EP3493830B1 (en) * 2016-08-04 2025-12-03 Takeda Pharmaceutical Company Limited Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
IL266264B2 (en) 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
PL3639845T3 (pl) * 2017-07-25 2023-10-23 Jiangsu Hengrui Medicine Co., Ltd. Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
WO2020014479A1 (en) * 2018-07-11 2020-01-16 Baxalta Incorporated Aav compositions
EP4037704B1 (en) 2019-10-04 2025-12-03 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
EP4127158A2 (en) 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
CN115835904A (zh) 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法
IL300596A (en) * 2020-08-13 2023-04-01 Hadasit Medical Res Services & Development Limited Mutants of disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (adamts-13), preparations and their uses in therapeutic methods
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
EP1642128B1 (en) * 2003-07-07 2016-11-16 University Of North Carolina At Chapel Hill Method and system for detection of von willebrand factor (vwf) multimers
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2606351C (en) * 2005-06-17 2016-12-13 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
CA2633306A1 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
BR112012006283B1 (pt) * 2009-09-21 2022-03-15 Takeda Pharmaceutical Company Limited Formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e, usos de adamts13
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
CN104224705A (zh) 2014-12-24
EP4467160A2 (en) 2024-11-27
EP2480198B1 (en) 2016-03-09
US10238720B2 (en) 2019-03-26
US20230130866A1 (en) 2023-04-27
BR112012006283B1 (pt) 2022-03-15
CA2774556A1 (en) 2011-03-24
US20190247475A1 (en) 2019-08-15
PT4218797T (pt) 2024-12-09
CN102573792A (zh) 2012-07-11
ES2865250T3 (es) 2021-10-15
EA201200519A1 (ru) 2012-09-28
EP3834841B1 (en) 2023-05-17
KR20190137954A (ko) 2019-12-11
PT3834841T (pt) 2023-06-19
US12178861B2 (en) 2024-12-31
US20250099559A1 (en) 2025-03-27
HUE028688T2 (en) 2017-01-30
EP3834841A1 (en) 2021-06-16
EP2480198B9 (en) 2016-11-23
US20110229455A1 (en) 2011-09-22
US20200376098A1 (en) 2020-12-03
AU2010295299B2 (en) 2015-12-24
MX2019000547A (es) 2020-11-12
PL3167897T3 (pl) 2021-09-27
EP4218797B9 (en) 2025-04-30
US10758599B2 (en) 2020-09-01
EP3167897A1 (en) 2017-05-17
US9937244B2 (en) 2018-04-10
PL2480198T3 (pl) 2016-09-30
US20160375111A1 (en) 2016-12-29
ES3001509T3 (en) 2025-03-05
EP2480198A2 (en) 2012-08-01
DK4218797T5 (da) 2025-07-21
DK3167897T3 (da) 2021-04-19
FI4218797T3 (fi) 2024-12-07
ES2948612T3 (es) 2023-09-14
WO2011035335A2 (en) 2011-03-24
US9351935B2 (en) 2016-05-31
US20180207245A1 (en) 2018-07-26
US20170112906A1 (en) 2017-04-27
KR101891646B1 (ko) 2018-08-27
CN102573792B (zh) 2014-10-15
FI3834841T3 (fi) 2023-06-05
NZ598839A (en) 2014-03-28
PL4218797T3 (pl) 2025-02-10
US20140178357A1 (en) 2014-06-26
EP3167897B1 (en) 2021-01-27
EP4218797A1 (en) 2023-08-02
DK4218797T3 (da) 2024-12-09
MX2012003414A (es) 2012-06-19
KR20120099646A (ko) 2012-09-11
MX362382B (es) 2019-01-14
US11564979B2 (en) 2023-01-31
EA024267B1 (ru) 2016-09-30
AU2010295299A1 (en) 2012-04-12
HRP20160295T1 (hr) 2016-05-20
MX339205B (es) 2016-05-16
HK1173968A1 (zh) 2013-05-31
EP4467160A3 (en) 2025-01-15
FR24C1049I1 (fr) 2025-01-17
CN104224705B (zh) 2018-02-02
KR20250008986A (ko) 2025-01-16
BR112012006283A2 (pt) 2016-05-31
US9572778B2 (en) 2017-02-21
JP2015063556A (ja) 2015-04-09
FR24C1049I2 (fr) 2025-12-12
KR20220139456A (ko) 2022-10-14
US8623352B2 (en) 2014-01-07
JP2013505270A (ja) 2013-02-14
JP5819303B2 (ja) 2015-11-24
EP4218797B1 (en) 2024-09-11
PL3834841T3 (pl) 2023-07-24
KR20180095738A (ko) 2018-08-27
WO2011035335A3 (en) 2011-12-01
DK2480198T3 (en) 2016-03-29
IN2012DN02645A (enExample) 2015-09-11
ES2579906T3 (es) 2016-08-17
DK3834841T3 (da) 2023-06-06

Similar Documents

Publication Publication Date Title
US12178861B2 (en) Stabilized liquid and lyophilized ADAMTS13 formulations
HK40120000A (en) Stabilized liquid and lyophilized adamts13 formulations
HK40097428B (en) Stabilized liquid and lyophilized adamts13 formulations
HK40097428A (en) Stabilized liquid and lyophilized adamts13 formulations
HK40051221B (en) Stabilized liquid and lyophilized adamts13 formulations
HK40051221A (en) Stabilized liquid and lyophilized adamts13 formulations
HK1237675B (en) Stabilized liquid and lyophilized adamts13 formulations
HK1173968B (en) Stabilized liquid and lyophilized adamts13 formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000